Does ketamine treat treatment-resistant depression?
Strong EvidenceYES
Ketamine produces rapid antidepressant effects within hours in treatment-resistant depression patients, a breakthrough finding replicated across multiple RCTs. However, effects are short-lived (days to weeks) and concerns about side effects, abuse potential, and long-term safety remain.
The Verdict
Ketamine produces rapid antidepressant effects within hours in treatment-resistant depression patients, a breakthrough finding replicated across multiple RCTs. However, effects are short-lived (days to weeks) and concerns about side effects, abuse potential, and long-term safety remain.
What the Evidence Shows
Ketamine's rapid antidepressant properties represent one of the most significant advances in depression treatment in decades. Zarate et al. (2006) published the landmark proof-of-concept RCT demonstrating that a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) produced significant antidepressant effects within 2 hours in treatment-resistant depression (TRD) patients, with 71% responding at 24 hours. This was revolutionary because traditional antidepressants require 2-6 weeks for therapeutic onset. Murrough et al. (2013) confirmed these findings in a larger multicenter trial, showing 64% response rate at 24 hours versus 28% with active placebo. The Cochrane review by Caddy et al. (2015) synthesized available evidence confirming short-term efficacy. Ketamine acts as an NMDA receptor antagonist, with downstream effects on AMPA receptor signaling, BDNF release, and rapid synaptogenesis in the prefrontal cortex. This mechanism is fundamentally different from traditional monoamine-based antidepressants. The FDA approved esketamine (Spravato) nasal spray for TRD in 2019 based on this evidence. However, significant limitations exist: the antidepressant effect typically wears off within 1-2 weeks without repeated dosing, requiring ongoing maintenance infusions. Dissociative side effects, blood pressure elevation, cognitive effects, and abuse potential remain concerning, particularly with long-term repeated use.
Evidence Quality
2
Meta-Analyses
8
RCTs
5
Observational
Important Caveats
- ⚠️ Antidepressant effects are rapid but short-lived (typically 1-2 weeks without redosing)
- ⚠️ Requires repeated infusions for sustained benefit, with unclear long-term safety
- ⚠️ Dissociative and psychotomimetic side effects occur in many patients
- ⚠️ Abuse and dependence potential requires careful patient selection and monitoring
- ⚠️ Long-term neurocognitive effects of repeated ketamine exposure are unknown
Population Studied
Adults with treatment-resistant major depressive disorder (failed 2+ adequate antidepressant trials); some studies in suicidal ideation
Dosage
Standard IV dose: 0.5 mg/kg infused over 40 minutes; esketamine nasal spray: 56-84 mg twice weekly initially, then weekly/biweekly
Duration
Effects onset within 2-4 hours; peak at 24 hours; typically wane by 7-14 days without maintenance dosing
Supporting Studies (3)
Ketamine and other glutamate receptor modulators for depression in adults
Meta-AnalysisCaddy C, Amit BH, McCloud TL, et al. · Cochrane Database of Systematic Reviews (2015)
Cochrane review found ketamine demonstrated rapid antidepressant effects compared to placebo within 24 hours in TRD patients, though evidence certainty was limited by small trial sizes and short follow-up.
View paper (DOI) →A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
RCTZarate CA, Singh JB, Carlson PJ, et al. · Archives of General Psychiatry (2006)
Landmark crossover RCT showed single IV ketamine infusion produced significant antidepressant effects within 2 hours in TRD patients, with 71% response rate at 24 hours versus 0% for placebo.
View paper (DOI) →Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
RCTMurrough JW, Iosifescu DV, Chang LC, et al. · American Journal of Psychiatry (2013)
Multicenter RCT confirmed ketamine's rapid antidepressant effects with 64% response rate at 24 hours compared to 28% with active placebo (midazolam), validating the initial proof-of-concept findings.
View paper (DOI) →Contradicting Studies (1)
Side effects associated with ketamine use in depression: a systematic review
Meta-AnalysisShort B, Fong J, Galvez V, et al. · The Lancet Psychiatry (2018)
Systematic review documented significant side effect burden including dissociation, elevated blood pressure, headache, and cognitive effects, raising concerns about repeated long-term use for chronic depression management.
Why this disagrees:
While not questioning short-term efficacy, highlights that the side effect profile and abuse potential may limit clinical utility for the repeated long-term administration needed to maintain antidepressant effects.
Related Claims
Does CBT effectively treat anxiety disorders?
Strong EvidenceCognitive behavioral therapy (CBT) is well-established as an effective treatment for anxiety disorders, with large effect sizes demonstrated across multiple meta-analyses. It is considered first-line treatment by major clinical guidelines.
Does exercise treat depression as effectively as medication?
Strong EvidenceStrong evidence shows regular exercise is an effective treatment for mild to moderate depression, with effects comparable to antidepressant medication. Exercise appears most effective when performed at moderate-to-vigorous intensity 3-5 times per week.